JOINN Laboratories (China) Co., Ltd. Class H (HK:6127)
:6127
Want to see HK:6127 full AI Analyst Report?
Top Page
JOINN Laboratories (China) Co., Ltd. Class H
(6127)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$19.00
â–Ľ(-10.04% Downside)
Action:Reiterated
Date:05/02/26
The score is driven primarily by a very strong, low-debt balance sheet and reasonable valuation support (moderate P/E and very high dividend yield). Offsetting these positives are uneven operating performance (multi-year revenue contraction and compressed margins) and volatile free cash flow, while technical indicators are broadly neutral.
Positive Factors
Balance Sheet Strength
Extremely low leverage and an equity-heavy capital structure provide durable financial flexibility. This reduces refinancing risk, supports sustained investment in labs and equipment, and helps the firm absorb cyclical declines in client project volumes without jeopardizing operations.
Negative Factors
Multi-year Revenue Contraction
A multi-year top-line decline indicates weakening demand or lost projects versus peers. Even with a recent rebound, the prior contraction makes revenue visibility and planning harder, limiting long-term capacity utilization and investment pacing over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and an equity-heavy capital structure provide durable financial flexibility. This reduces refinancing risk, supports sustained investment in labs and equipment, and helps the firm absorb cyclical declines in client project volumes without jeopardizing operations.
Read all positive factors
JOINN Laboratories (China) Co., Ltd. Class H (6127) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.77B
Dividend Yield0.15%
Average Volume (3M)6.46M
Price to Earnings (P/E)49.0
Beta (1Y)1.56
Revenue Growth-13.51%
EPS Growth33.63%
CountryHK
Employees2,510
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.66
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.80Price Target Upside-20.45% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.63
Revenue Forecast (FY)HK$2.21B
JOINN Laboratories (China) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Relat...
How the Company Makes Money
JOINN Laboratories (China) Co., Ltd. primarily makes money by charging customers (pharma, biotech, and medical device companies) service fees under contract research arrangements for outsourced R&D work. Key revenue streams typically include (i) n...
JOINN Laboratories (China) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
92
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.69B | 1.66B | 2.02B | 2.38B | 2.27B | 1.52B |
| Gross Profit | 325.85M | 343.31M | 573.77M | 1.01B | 1.09B | 739.12M |
| EBITDA | 455.02M | 483.24M | 234.36M | 639.52M | 1.36B | 738.86M |
| Net Income | 495.07M | 297.84M | 74.08M | 396.99M | 1.07B | 557.46M |
Balance Sheet | ||||||
| Total Assets | 10.04B | 9.68B | 9.40B | 10.03B | 10.36B | 8.54B |
| Cash, Cash Equivalents and Short-Term Investments | 2.49B | 2.63B | 2.36B | 4.77B | 3.33B | 4.84B |
| Total Debt | 12.48M | 1.42M | 21.60M | 41.92M | 87.71M | 95.32M |
| Total Liabilities | 1.48B | 1.36B | 1.32B | 1.75B | 2.17B | 1.39B |
| Stockholders Equity | 8.56B | 8.32B | 8.08B | 8.28B | 8.18B | 7.14B |
Cash Flow | ||||||
| Free Cash Flow | 83.60M | 300.96M | 69.54M | 430.15M | 696.23M | 448.41M |
| Operating Cash Flow | 550.77M | 444.57M | 338.93M | 622.88M | 971.07M | 685.66M |
| Investing Cash Flow | -174.64M | -419.19M | -1.96B | -315.43M | -2.16B | -2.07B |
| Financing Cash Flow | -53.96M | -66.98M | -265.63M | -361.68M | -99.33M | 5.29B |
JOINN Laboratories (China) Co., Ltd. Class H Technical Analysis
Negative
21.12
Price Trends
20.28
Negative
21.16
Negative
20.92
Negative
Market Momentum
-0.97
Positive
35.92
Neutral
12.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6127, the sentiment is Negative. The current price of 21.12 is above the 20-day moving average (MA) of 19.16, above the 50-day MA of 20.28, and above the 200-day MA of 20.92, indicating a bearish trend. The MACD of -0.97 indicates Positive momentum. The RSI at 35.92 is Neutral, neither overbought nor oversold. The STOCH value of 12.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6127.
JOINN Laboratories (China) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$332.18B | 14.03 | 28.07% | 1.84% | 19.90% | 86.59% | |
74 Outperform | HK$25.77B | 49.05 | 5.98% | 0.15% | -13.51% | 33.63% | |
70 Outperform | HK$47.26B | 37.94 | 6.34% | 1.57% | 18.78% | 12.65% | |
68 Neutral | HK$44.63B | 24.56 | 11.22% | 1.04% | 16.83% | -8.65% | |
62 Neutral | HK$34.58B | 41.24 | 3.69% | 0.80% | 10.65% | 134.38% | |
54 Neutral | HK$28.13B | -6.75 | -12.72% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
17.00
2.23
15.10%
HK:1548
Genscript Biotech
12.92
-4.06
-23.91%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
31.70
-5.60
-15.01%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
16.47
0.40
2.51%
HK:2359
WuXi AppTec Co., Ltd. Class H
124.50
52.50
72.91%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
93.50
17.59
23.17%
JOINN Laboratories (China) Co., Ltd. Class H Corporate Events
JOINN Laboratories Creates Strategic Development Committee to Tighten Investment and Governance Oversight
Jun 4, 2026
JOINN Laboratories (China) Co., Ltd. has established a Strategic Development Committee under its board of directors to enhance long-term planning and oversight of major investments and capital operations. The committee is composed of at least four...
JOINN Laboratories Refines 2026 Restricted A Share Incentive Scheme and Confirms Treasury-Funded Grants
Jun 4, 2026
JOINN Laboratories (China) Co., Ltd. announced adjustments to the participant list and grant amounts under its 2026 Restricted A Share Incentive Scheme, and confirmed the grant of restricted A shares funded from treasury stock to eligible staff at...
JOINN Laboratories Approves Dividend, Board Changes at 2025 AGM and 2026 Class Meetings
Jun 4, 2026
JOINN Laboratories reported the poll results of its 2025 annual general meeting and separate 2026 A and H share class meetings held in Beijing, confirming that all sessions were duly convened with directors present and no compulsory abstentions un...
JOINN Laboratories Sets Final 2025 Dividend and Clarifies Tax Treatment for Hong Kong Shareholders
Jun 4, 2026
JOINN Laboratories (China) Co., Ltd., listed in Hong Kong under stock code 06127, operates in the biomedical and pharmaceutical services industry, providing laboratory-based support for drug research and development. Its client base typically incl...
JOINN Laboratories Updates Board Composition and Committee Roles
Jun 4, 2026
JOINN Laboratories (China) Co., Ltd. has released an updated list of its directors and detailed their roles and functions across key board committees. The announcement clarifies which board members chair or serve on the Strategic Development, Remu...
JOINN Laboratories sets 2025 AGM to approve profit distribution and new share incentive plan
May 12, 2026
JOINN Laboratories (China) Co., Ltd. has convened its 2025 annual general meeting for June 4, 2026 in Beijing, where shareholders will review the 2025 annual report, board work report and a proposed profit distribution plan. The meeting will also ...
JOINN Laboratories Calls 2026 H Share Class Meeting to Amend Governance Rules
May 12, 2026
JOINN Laboratories has called its first H share class meeting of 2026, to be held in Beijing on 4 June 2026 following its 2025 annual general meeting and the A share class meeting. H share investors on the register as of that date will be able to ...
JOINN Laboratories Updates Final 2025 Dividend Details and Investor Timetable
May 12, 2026
JOINN Laboratories (China) Co., Ltd., a China-based contract research provider to pharmaceutical and biotech clients, has its H shares listed in Hong Kong, where overseas and institutional investors can participate in the company’s growth. I...
JOINN Laboratories Grants New Three-Year H-Share Awards to Management
Apr 30, 2026
JOINN Laboratories (China) Co., Ltd. has granted 1,430,000 H-share awards, equal to about 1.20% of its issued H shares and 0.191% of total share capital, to 12 selected participants under its existing share incentive scheme. The grant, which inclu...
JOINN Laboratories Launches 2026 Restricted A Share Incentive Scheme Using Treasury Stock
Apr 29, 2026
JOINN Laboratories (China) Co., Ltd. has unveiled a 2026 Restricted A Share Incentive Scheme funded by treasury A shares, alongside related assessment measures, as disclosed on the Shanghai Stock Exchange. The plan, which targets directors and sup...
JOINN Laboratories’ First-Quarter Profit Soars on Strong Operational Performance
Apr 29, 2026
JOINN Laboratories (China) reported robust unaudited results for the first quarter of 2026, with revenue rising 10.02% year on year to RMB316.1 million and net profit attributable to shareholders surging 479.67% to RMB238.4 million. Profitability ...
JOINN Laboratories Sets Board Meeting to Approve First-Quarter 2026 Results
Apr 17, 2026
JOINN Laboratories (China) Co., Ltd., a PRC-incorporated company listed on the Hong Kong Stock Exchange, operates through a group structure overseen by a diversified board that includes executive, independent non-executive and employee directors. ...
JOINN Laboratories Profit Jumps on Fair-Value Gains Despite Revenue Decline in 2025
Mar 30, 2026
JOINN Laboratories reported audited 2025 results showing revenue of RMB1.66 billion, down 17.9% year-on-year, and gross profit of RMB281.06 million, a 44.4% decline, reflecting weaker top-line performance and margin pressure in its research servic...
JOINN Laboratories Announces Final 2025 Cash Dividend and Tax Treatment for H Shareholders
Mar 30, 2026
JOINN Laboratories (China) Co., Ltd. has announced a proposed final cash dividend of RMB 0.12 per share for the financial year ended 31 December 2025, with payment to eligible shareholders expected by no later than 31 August 2026. The dividend wil...
JOINN Laboratories Overhauls Governance Rules and Adds Non-Executive Director
Mar 30, 2026
JOINN Laboratories (China) Co., Ltd. has announced a package of corporate governance changes, including proposed amendments to its Articles of Association and the rules of procedures for shareholders’ general meetings, as well as the nominat...
JOINN Laboratories Sets March 2026 Board Meeting to Approve 2025 Results
Mar 18, 2026
JOINN Laboratories (China) Co., Ltd. has scheduled a board meeting for 30 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend f...
JOINN Laboratories’ CITIC Product Holdings Reach RMB460 Million, Triggering Discloseable Transaction
Mar 16, 2026
JOINN Laboratories has increased its investments in financial products issued by CITIC Securities and its subsidiaries, with the aggregate outstanding investment now reaching RMB460 million as of 16 March 2026. The company states that all earlier ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.